Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain

W. G. Mantyh, J. M. Jimenez-Andrade, J. I. Stake, A. P. Bloom, M. J. Kaczmarska, R. N. Taylor, K. T. Freeman, J. R. Ghilardi, M. A. Kuskowski, Patrick W Mantyh

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

For many patients, pain is the first sign of cancer and, while pain can be present at any time, the frequency and intensity of pain tend to increase with advancing stages of the disease. Thus, between 75 and 90% of patients with metastatic or advanced-stage cancer will experience significant cancer-induced pain. One major unanswered question is why cancer pain increases and frequently becomes more difficult to fully control with disease progression. To gain insight into this question we used a mouse model of bone cancer pain to demonstrate that as tumor growth progresses within bone, tropomyosin receptor kinase A (TrkA)-expressing sensory and sympathetic nerve fibers undergo profuse sprouting and form neuroma-like structures. To address what is driving the pathological nerve reorganization we administered an antibody to nerve growth factor (anti-NGF). Early sustained administration of anti-NGF, whose cognate receptor is TrkA, blocks the pathological sprouting of sensory and sympathetic nerve fibers, the formation of neuroma-like structures, and inhibits the development of cancer pain. These results suggest that cancer cells and their associated stromal cells release nerve growth factor (NGF), which induces a pathological remodeling of sensory and sympathetic nerve fibers. This pathological remodeling of the peripheral nervous system then participates in driving cancer pain. Similar to therapies that target the cancer itself, the data presented here suggest that, the earlier therapies blocking this pathological nerve remodeling are initiated, the more effective the control of cancer pain.

Original languageEnglish (US)
Pages (from-to)588-598
Number of pages11
JournalNeuroscience
Volume171
Issue number2
DOIs
StatePublished - Dec 1 2010

Fingerprint

Neuroma
Nerve Block
Adrenergic Fibers
Nerve Growth Factor
Nerve Fibers
Neoplasms
Pain
Bone Neoplasms
Antibodies
Peripheral Nervous System
Stromal Cells
Secondary Prevention
Cancer Pain
Disease Progression
Bone and Bones
Growth

Keywords

  • Breakthrough pain
  • Periosteum
  • Preventive analgesia

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Mantyh, W. G., Jimenez-Andrade, J. M., Stake, J. I., Bloom, A. P., Kaczmarska, M. J., Taylor, R. N., ... Mantyh, P. W. (2010). Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain. Neuroscience, 171(2), 588-598. https://doi.org/10.1016/j.neuroscience.2010.08.056

Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain. / Mantyh, W. G.; Jimenez-Andrade, J. M.; Stake, J. I.; Bloom, A. P.; Kaczmarska, M. J.; Taylor, R. N.; Freeman, K. T.; Ghilardi, J. R.; Kuskowski, M. A.; Mantyh, Patrick W.

In: Neuroscience, Vol. 171, No. 2, 01.12.2010, p. 588-598.

Research output: Contribution to journalArticle

Mantyh, WG, Jimenez-Andrade, JM, Stake, JI, Bloom, AP, Kaczmarska, MJ, Taylor, RN, Freeman, KT, Ghilardi, JR, Kuskowski, MA & Mantyh, PW 2010, 'Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain', Neuroscience, vol. 171, no. 2, pp. 588-598. https://doi.org/10.1016/j.neuroscience.2010.08.056
Mantyh, W. G. ; Jimenez-Andrade, J. M. ; Stake, J. I. ; Bloom, A. P. ; Kaczmarska, M. J. ; Taylor, R. N. ; Freeman, K. T. ; Ghilardi, J. R. ; Kuskowski, M. A. ; Mantyh, Patrick W. / Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain. In: Neuroscience. 2010 ; Vol. 171, No. 2. pp. 588-598.
@article{821fff57a345493e8b1f56a19ed5671c,
title = "Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain",
abstract = "For many patients, pain is the first sign of cancer and, while pain can be present at any time, the frequency and intensity of pain tend to increase with advancing stages of the disease. Thus, between 75 and 90{\%} of patients with metastatic or advanced-stage cancer will experience significant cancer-induced pain. One major unanswered question is why cancer pain increases and frequently becomes more difficult to fully control with disease progression. To gain insight into this question we used a mouse model of bone cancer pain to demonstrate that as tumor growth progresses within bone, tropomyosin receptor kinase A (TrkA)-expressing sensory and sympathetic nerve fibers undergo profuse sprouting and form neuroma-like structures. To address what is driving the pathological nerve reorganization we administered an antibody to nerve growth factor (anti-NGF). Early sustained administration of anti-NGF, whose cognate receptor is TrkA, blocks the pathological sprouting of sensory and sympathetic nerve fibers, the formation of neuroma-like structures, and inhibits the development of cancer pain. These results suggest that cancer cells and their associated stromal cells release nerve growth factor (NGF), which induces a pathological remodeling of sensory and sympathetic nerve fibers. This pathological remodeling of the peripheral nervous system then participates in driving cancer pain. Similar to therapies that target the cancer itself, the data presented here suggest that, the earlier therapies blocking this pathological nerve remodeling are initiated, the more effective the control of cancer pain.",
keywords = "Breakthrough pain, Periosteum, Preventive analgesia",
author = "Mantyh, {W. G.} and Jimenez-Andrade, {J. M.} and Stake, {J. I.} and Bloom, {A. P.} and Kaczmarska, {M. J.} and Taylor, {R. N.} and Freeman, {K. T.} and Ghilardi, {J. R.} and Kuskowski, {M. A.} and Mantyh, {Patrick W}",
year = "2010",
month = "12",
day = "1",
doi = "10.1016/j.neuroscience.2010.08.056",
language = "English (US)",
volume = "171",
pages = "588--598",
journal = "Neuroscience",
issn = "0306-4522",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain

AU - Mantyh, W. G.

AU - Jimenez-Andrade, J. M.

AU - Stake, J. I.

AU - Bloom, A. P.

AU - Kaczmarska, M. J.

AU - Taylor, R. N.

AU - Freeman, K. T.

AU - Ghilardi, J. R.

AU - Kuskowski, M. A.

AU - Mantyh, Patrick W

PY - 2010/12/1

Y1 - 2010/12/1

N2 - For many patients, pain is the first sign of cancer and, while pain can be present at any time, the frequency and intensity of pain tend to increase with advancing stages of the disease. Thus, between 75 and 90% of patients with metastatic or advanced-stage cancer will experience significant cancer-induced pain. One major unanswered question is why cancer pain increases and frequently becomes more difficult to fully control with disease progression. To gain insight into this question we used a mouse model of bone cancer pain to demonstrate that as tumor growth progresses within bone, tropomyosin receptor kinase A (TrkA)-expressing sensory and sympathetic nerve fibers undergo profuse sprouting and form neuroma-like structures. To address what is driving the pathological nerve reorganization we administered an antibody to nerve growth factor (anti-NGF). Early sustained administration of anti-NGF, whose cognate receptor is TrkA, blocks the pathological sprouting of sensory and sympathetic nerve fibers, the formation of neuroma-like structures, and inhibits the development of cancer pain. These results suggest that cancer cells and their associated stromal cells release nerve growth factor (NGF), which induces a pathological remodeling of sensory and sympathetic nerve fibers. This pathological remodeling of the peripheral nervous system then participates in driving cancer pain. Similar to therapies that target the cancer itself, the data presented here suggest that, the earlier therapies blocking this pathological nerve remodeling are initiated, the more effective the control of cancer pain.

AB - For many patients, pain is the first sign of cancer and, while pain can be present at any time, the frequency and intensity of pain tend to increase with advancing stages of the disease. Thus, between 75 and 90% of patients with metastatic or advanced-stage cancer will experience significant cancer-induced pain. One major unanswered question is why cancer pain increases and frequently becomes more difficult to fully control with disease progression. To gain insight into this question we used a mouse model of bone cancer pain to demonstrate that as tumor growth progresses within bone, tropomyosin receptor kinase A (TrkA)-expressing sensory and sympathetic nerve fibers undergo profuse sprouting and form neuroma-like structures. To address what is driving the pathological nerve reorganization we administered an antibody to nerve growth factor (anti-NGF). Early sustained administration of anti-NGF, whose cognate receptor is TrkA, blocks the pathological sprouting of sensory and sympathetic nerve fibers, the formation of neuroma-like structures, and inhibits the development of cancer pain. These results suggest that cancer cells and their associated stromal cells release nerve growth factor (NGF), which induces a pathological remodeling of sensory and sympathetic nerve fibers. This pathological remodeling of the peripheral nervous system then participates in driving cancer pain. Similar to therapies that target the cancer itself, the data presented here suggest that, the earlier therapies blocking this pathological nerve remodeling are initiated, the more effective the control of cancer pain.

KW - Breakthrough pain

KW - Periosteum

KW - Preventive analgesia

UR - http://www.scopus.com/inward/record.url?scp=78149280765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149280765&partnerID=8YFLogxK

U2 - 10.1016/j.neuroscience.2010.08.056

DO - 10.1016/j.neuroscience.2010.08.056

M3 - Article

C2 - 20851743

AN - SCOPUS:78149280765

VL - 171

SP - 588

EP - 598

JO - Neuroscience

JF - Neuroscience

SN - 0306-4522

IS - 2

ER -